CareDx’s plans to acquire Naveris follow the divestment of its lab products business earlier this month, reporting flat revenue for the segment in Q1.

Avatar’s software translates CT and MR imaging data into 3D images to streamline surgical planning and operating room workflows.

Abbott has received the US FDA approval and CE Mark for its Ultreon 3.0 artificial intelligence (AI)-powered coronary imaging platform.

Medtronic has received the CE mark for the Stealth AXiS surgical platform that combines planning, navigation, and robotics into one system.

According to GlobalData analyst Dr Andrew S Thompson, the deal signals Thermo Fisher’s move away from the IVD space.

Merck KGaA and Remepy will work in tandem to develop drug-digital therapy combinations for a rare cancer indication.

Tandem has received FDA approval for its Control-IQ+ automated insulin delivery technology to be used during pregnancy in individuals with type 1 diabetes mellitus.

Nervonik has secured $52.5m in Series B financing aimed at advancing its peripheral nerve stimulation (PNS) system.

New data on the pulsed-field ablation (PFA) device class debuts at HRS 2026 as the field catches the eye of several large medtech companies.

Motif’s study primarily aims to validate the safety of its XCS system over a 12-month period following implantation.

Should the transaction complete, J&J will inherit Atraverse’s radiofrequency system for simplifying access to the heart’s left atrium.

Adagio Medical has reported positive six-month data from its FULCRUM-VT trial, supporting its plans to seek FDA premarket approval for the vCLAS system.